Investigational Site Number :7240002

Madrid / Madrid, Madrid, Comunidad de 28050

0 studies enrolling now · 3 studies all time

What they study most

Alport Syndrome, Breast Cancer, Gastric Cancer, Lung Neoplasm Malignant, Neoplasm, Neoplasm Malignant

Studies at this site

• Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors — Stopped early
• Study of Lademirsen (SAR339375) in Patients With Alport Syndrome — Stopped early
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early